Genmab Announces that Janssen has Received Positive CHMP Opinion for RYBREVANT® (amivantamab) for Patients with Advanced Non-small Cell Lung Cancer…

Posted: October 16, 2021 at 2:47 am

Media ReleaseCopenhagen, Denmark, October 15, 2021

Read this article:
Genmab Announces that Janssen has Received Positive CHMP Opinion for RYBREVANT® (amivantamab) for Patients with Advanced Non-small Cell Lung Cancer...

Related Posts